SCHEMBL6347883

SCHEMBL6347883

CC(NC(=O)OC(C)(C)C)C(=O)Nc1ccc(Sc2ccccc2)cc1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 1/20 0.47
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
HPGD P15428 1/20 0.40
HTT P42858 1/20 0.40
SUV39H2 Q9H5I1 1/20 0.39
ADORA3 P0DMS8 2/20 0.39
GRM4 Q14833 1/20 0.38
GLS O94925 1/20 0.38
AAK1 Q2M2I8 3/20 0.38
HDAC1 Q13547 1/20 0.38
CTSS P25774 1/20 0.37
CTSK P43235 1/20 0.37
KMT2A Q03164 2/20 0.37
MEN1 O00255 1/20 0.37
THRB P10828 1/20 0.37
KLK5 Q9Y337 1/20 0.37
TAS1R3 Q7RTX0 1/20 0.36
TAS1R1 Q7RTX1 1/20 0.36
ATM Q13315 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6347878 1.00 MMP13 (0.47) MMP13KDM4EALDH1A1HPGDHTT
SCHEMBL6351344 0.80 POLB (0.42) MMP13KDM4EALDH1A1HPGDHTT
SCHEMBL6351340 0.80 POLB (0.42) MMP13KDM4EALDH1A1HPGDHTT
SCHEMBL31045384 0.78 AAK1 (0.41) SUV39H2ADORA3GLSAAK1KMT2A
SCHEMBL27760534 0.76 HDAC2 (0.48) KDM4EALDH1A1HPGDHTTGLS
SCHEMBL27760532 0.75 SUV39H2 (0.40) KDM4EHPGDSUV39H2ADORA3GLS
SCHEMBL11901158 0.75 ADORA3 (0.45) KDM4EALDH1A1HPGDHTTSUV39H2
SCHEMBL1752734 0.75 MEN1 (0.53) KMT2AMEN1
SCHEMBL13258279 0.74 HDAC8 (0.51) ALDH1A1GLSHDAC1CTSSCTSK
SCHEMBL13258134 0.74 HDAC8 (0.51) ALDH1A1GLSHDAC1CTSSCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6960688-B2 Use of compounds for the elevation of pyruvate dehydrogenase activity ASTRAZENECA AB (SE) 2005-11-01 US disclosed
EP-1082110-B1 USE OF COMPOUNDS FOR THE ELEVATION OF PYRUVATE DEHYDROGENASE ACTIVITY ASTRAZENECA AB (SE) 2004-03-24 EP disclosed
US-20040009979-A1 Use of compounds for the elevation of pyruvate dehydrogenase activity ZENECA LIMITED 2004-01-15 US disclosed
US-6498275-B1 Use of compounds for the elevation of pyruvate dehydrogenase activity ASTRAZENECA AB (SE) 2002-12-24 US disclosed
CN-1303281-A Application of compound in enhancing activity of pyruvate dehydrogenase ASTRA ZENECA LTD (SE) 2001-07-11 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009979-A1 Use of compounds for the elevation of pyruvate dehydrogenase activity PDHA1, PDK1, PDHB MMP13 2598/4885KDM4E 1225/4885ALDH1A1 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.